收费全文 | 25622篇 |
免费 | 1349篇 |
国内免费 | 65篇 |
耳鼻咽喉 | 364篇 |
儿科学 | 2029篇 |
妇产科学 | 609篇 |
基础医学 | 2944篇 |
口腔科学 | 452篇 |
临床医学 | 1390篇 |
内科学 | 4741篇 |
皮肤病学 | 987篇 |
神经病学 | 1133篇 |
特种医学 | 949篇 |
外科学 | 3847篇 |
综合类 | 912篇 |
一般理论 | 10篇 |
预防医学 | 1260篇 |
眼科学 | 1286篇 |
药学 | 2115篇 |
中国医学 | 144篇 |
肿瘤学 | 1864篇 |
2023年 | 124篇 |
2022年 | 298篇 |
2021年 | 723篇 |
2020年 | 405篇 |
2019年 | 471篇 |
2018年 | 685篇 |
2017年 | 452篇 |
2016年 | 655篇 |
2015年 | 578篇 |
2014年 | 908篇 |
2013年 | 1078篇 |
2012年 | 1516篇 |
2011年 | 1620篇 |
2010年 | 879篇 |
2009年 | 708篇 |
2008年 | 1232篇 |
2007年 | 1307篇 |
2006年 | 1126篇 |
2005年 | 1063篇 |
2004年 | 957篇 |
2003年 | 890篇 |
2002年 | 798篇 |
2001年 | 723篇 |
2000年 | 683篇 |
1999年 | 597篇 |
1998年 | 244篇 |
1997年 | 179篇 |
1996年 | 144篇 |
1995年 | 136篇 |
1994年 | 114篇 |
1993年 | 131篇 |
1992年 | 356篇 |
1991年 | 390篇 |
1990年 | 342篇 |
1989年 | 358篇 |
1988年 | 308篇 |
1987年 | 277篇 |
1986年 | 269篇 |
1985年 | 279篇 |
1984年 | 219篇 |
1983年 | 181篇 |
1979年 | 241篇 |
1978年 | 158篇 |
1977年 | 148篇 |
1976年 | 135篇 |
1975年 | 163篇 |
1974年 | 154篇 |
1973年 | 176篇 |
1972年 | 138篇 |
1971年 | 122篇 |
Background
Multiple myeloma (MM) is a hematologic malignancy of plasma cell origin. MM primarily affects bone marrow, but extramedullary sites can also be involved. Myelomatous pleural effusion (MPE) is an atypical and rare complication of MM. We aimed to systematically study the incidence and clinicopathologic profile of patients with MPE in a real-world setting.Patients and Methods
In this retrospective study, 415 consecutive patients with MM managed at a tertiary care center in North India during a study period of January 1, 2010 to December 31, 2015 were evaluated for MPE. The patients with MPE were analyzed for their clinical profile, diagnosis, treatment, and outcomes.Results
Of these 415 patients, 11 (2.65%) patients had MPE. The median age of the study population was 50 years with male preponderance. The majority of these patients had immunoglobin (Ig)G Kappa disease. All patients had higher than International Staging System stage I disease. MPE was a presenting feature at MM diagnosis in 45.45% (n = 5) of the patients, whereas the rest developed MPE during follow-up. MPE presented predominantly (81.8%) as a unilateral effusion. Concurrent extramedullary involvement at other site was seen in 45.45% (n = 5), with 3 (27%) patients having concurrent myelomatous ascites. Six of these were managed aggressively, whereas 5 patients opted for palliation. The outcomes were dismal (90.9% mortality), with a median survival of 2.47 months.Conclusion
MPE is a rare entity, and positive outcomes of therapy remain low with dismal prognosis. 相似文献Areas covered: This review comprises a summary of patent applications (2013–2018) of SGLT2 inhibitors with focus on chemical structural advancement and therapeutic potentials in the management of diabetes and related disorders.
Expert opinion: SGLT2 inhibitors exert multiple metabolic benefits, including reduced glycated hemoglobin (HbA1c), improved glycemic control (fasting and postprandial), reduced body weight, reduced systolic and diastolic blood pressure and improved HDL cholesterol. Due to the virtue of no interference with insulin action and secretion, their efficacy remains the same even in presence of progressive β cell failure in type 2 diabetes. Additionally, few members of this class have been reported to exhibit cardioprotective, renoprotective, and anticancer activity. However, more study on the long-term outcomes in patients taking SGLT2 inhibitors is warranted. 相似文献